Market research
CEPS.F CTI BioPharma Corp
F EUR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.83
Community
Investor discussion
1 comment
Sign in to join the CEPS.F discussion.
5 years, 5 months ago
CTI BioPharma Corp is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 93.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 85.7.
CTI BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 83.2% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.7% to $-11M since the same quarter in the previous year.
Based on the above factors, CTI BioPharma Corp gets an overall score of 2/5.